TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文
About Us About Us

Our Mission

Employ cutting-edge technology to discover and deliver high quality innovative biologics at affordable price to patients around the world.


We are a group of people with passion and experience for developing innovative medicines to serve patients around the world. We operate globally and focus on biologics, and we have established a fully integrated capability with a Discovery, Translational and Clinical Research Center in Suzhou, a Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Shanghai, Beijing and Princeton, US, and an External Partnering Center in Boston, US. 

Drug Discovery

Our Team

Leadership Leadership
Advisors Advisors


Oct 2012
Mabspace established
Jun 2013
Immune Tolerance Breaking Technology Platform developed
Mar 2015
Partnership with Hengrui & GenorBio
Oct 2015
Mabspace completed series A US$ 15M
Aug 2016
HJB established and completed series A US$ 10M
Mar 2017
Partnership with G-CON to build T-BLOC facility in Hangzhou
Aug 2017
HJB completed series B US$ 37M
Feb 2018
US FDA approval of
Apr 2018
MSB2311 initiated Phase I clinical trial in US
May 2018
Mabspace completed series B US$ 40M
Jun 2018
HJB completed series B+ US$ 35M;
NMPA Approval of MSB2311 IND
Jul 2018
Innovation partnership with 908 Devices
Jan 2019
Mabspace & HJB merged to establish Transcenta
Mar 2019
In-licensed Blosozumab (TST002) from Eli Lilly
Jun 2019
NMPA approval of JCT205
Jan 2020
Transcenta completed series B+ US$ 100M
Apr 2020
NMPA and FDA Approval of TST001
Jul 2020
First Patient Dosed in Phase I Clinical Trial of TST001 in the US
Aug 2020
First Patient Dosed in Phase I Clinical Trial of TST001 in China
Dec 2020
Closes US$105 Million in Crossover Financing

Albert Zhu CPA

SVP Finance Business Operations

Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting. In addition, he also participated in a number of M&A consulting projects to assist domestic and foreign clients to carry out due diligence, design trading structure, to ensure smooth transactions, as well as to carry out the integration of the financial sector to improve the clients and the target companies’ financial system and processes. Albert has received his bachelor degree from Sun Yat-sen University and is a member of the CICPA and the ACCA.